Company Overview and News

 
Bouygues Weighs Bid With Co-Investors for Altice Unit - Bloomberg

2018-04-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Bouygues Weighs Bid With Co-Investors for Altice Unit - Bloomberg

2018-04-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
The Solar Highway That Can Recharge Electric Cars on the Move - Bloomberg

2018-04-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Bouygues SA 2017 Q4 - Results - Earnings Call Slides

2018-02-23 seekingalpha
The following slide deck was published by Bouygues SA in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

 
Bouygues' (BOUYF) CEO Martin Bouygues on Q4 2017 Results - Earnings Call Transcript

2018-02-22 seekingalpha
Ladies and gentlemen, thank you for being here. Let's begin as is customary now with the highlights of 2017. You'll see in greater detail our results and our profitability have increased sharply year-on-year. All our targets for 2017 were met or exceeded, and I'll come at that in detail a little bit further on. The group's businesses have strengthened their positions in their markets, and finally, the Board of Directors has proposed that the AGM approve a dividend increase of €0.
Upvote Downvote

2
Debt King Drahi builds a cable empire on credit

2017-12-09 thestar.com.my
PARIS: The best description of Patrick Drahi’s business model may be the one he gave last year in a talk at his alma mater. “I bought everything on credit,” he told students at French engineering school Polytechnique. “I didn’t take much risk. It’s the banks that lent everything.”
Upvote Downvote

 
Bouygues SA 2017 Q3 - Results - Earnings Call Slides

2017-11-18 seekingalpha
The following slide deck was published by Bouygues SA in conjunction with their 2017 Q3 earnings call.
Upvote Downvote

 
Paris Faces Tough Choice Between Olympics and Angry Commuters - Bloomberg

2017-10-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Siemens to merge rail operations with French rival Alstom

2017-09-27 livemint
Munich/Paris: Siemens AG and Alstom SA agreed to merge their rail businesses in a deal that brings together former arch-rivals from Germany and France to create a European transportation giant aimed at countering competition from China.
Upvote Downvote

 
Siemens, Alstom are said to finalize rail combination deal

2017-09-26 livemint
Frankfurt/Paris/Munich: Siemens AG and Alstom SA are nearing an agreement on a framework to combine their rail units, as the German and French engineering companies’ boards prepare to meet to sign off on a deal that would create a European transportation giant, according to people familiar with the negotiations.
Upvote Downvote

 
Siemens, Alstom Are Said to Finalize Rail Combination Deal - Bloomberg

2017-09-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
100 Days of the Big Gulf Feud: Now Pick Sides - Bloomberg

2017-09-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Paris 2024 Olympics Triggers Race for Contracts Worth Billions - Bloomberg

2017-09-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
BOUYGUES SA (BOUYY): The Perfect Mix of Value and Rising Earnings Estimates?

2017-07-11 zacks
Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends? Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; BOUYGUES SA UNSP (BOUYY - Free Report) . BOUYGUES in Focus BOUYY may be an interesting play thanks to its forward PE of 11.
Upvote Downvote

 
Bouygues (BOUYF): An Off-the-Radar Potential Winner

2017-07-10 zacks
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach. So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision. One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Bouygues SA .
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...